Low expression of immune checkpoint PD-1 (PLDCD1) and CTLA4 were observed (Supplementary Figure S5A), suggesting poor immune checkpoint blockade status, which is consistent with the low sensitivity of ovarian cancer to immune checkpoint therapy (43, 44). Here, CTLA4 is linked to ovarian cancer.